Mircea Manuc1, Carmen M Preda2, Corneliu P Popescu3, Cristian Baicuș4, Theodor Voiosu4, Corina S Pop5, Liana Gheorghe1, Ioan Sporea6, Anca Trifan7, Marcel Tanțău8, Alina Tanțău9, Emanoil Ceaușu3, Doina Proca1, Ileana Constantinescu1, Simona M Ruta3, Larisa E Fulger1, Mircea Diculescu1, Alexandru Oproiu10. 1. Gastroenterology and Hepatology Dept., Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 2. Gastroenterology and Hepatology Dept., Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. carmenmonica.preda@gmail.com. 3. Virology Dept., Victor Babes Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 4. Internal Medicine Dept., Colentina Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 5. Gastroenterology Dept., Emergency Universitary Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 6. Gastroenterology and Hepatology Dept., Timisoara Emergency Hospital, University of Medicine and Pharmacy, Timișoara, Romania. 7. Gastroenterology and Hepatology Dept., Gastroenterology and Hepatology Institute, Gr. T. Popa University of Medicine and Pharmacy, Iași, Romania. 8. Regional Institute of Gastroenterology and Hepatology, and Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. 9. 4th Medical Clinic, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca. 10. Dept. Gastroenter, Agrippa Ionescu Hospital, Bucharest, Romania.
Abstract
BACKGROUND AND AIMS: Literature data suggest that HCV genotype-1b is present in 93-99% of the Romanian patients infected with hepatitis C virus (HCV). We present the genotyping tests recently performed on patients with HCV and advanced fibrosis eligible for the Direct-Acting Antiviral (DAA) therapy, as well as the prevalence of these cases across Romania. METHODS: The genotyping method was performed on 7,421 HCV patients with advanced fibrosis. The detection method was automatic real time PCR platform M2000 (Abbott). Every subject was introduced into a database including age, sex, county and address. RESULTS: Genotype 1b was almost exclusively present: 7,392/7,421 (99.6%). Genotype 1b patients were 19.6% from Bucharest, 49% were males, with a median age of 60 years. Genotype non-1b was encountered in 29/7,421 subjects (0.4%), 62% were males, 69% from Bucharest and the median age was 52 years. Most of the subjects (75%) were in the 6th and 7th age decade. The prevalence of these cases varied significantly across Romanian counties: the highest was in Bucharest (61.3/105), Bihor (47/105), Iasi (46/105) and Constanta (43/105), and the lowest in Ilfov (2.8/105), Harghita (3.7/105), Covasna (5.4/105) and Maramures (8.8/105) (p<0.001). CONCLUSIONS: Genotype 1b is encountered in 99.6% of patients with chronic hepatitis C and advanced fibrosis from Romania. The presence of genotypes non-1b is more common in Bucharest, in males and at a younger age. There are significant differences regarding the distribution of these cases across Romania: the highest rates are in Bucharest, Bihor, Iasi and Constanta.
BACKGROUND AND AIMS: Literature data suggest that HCV genotype-1b is present in 93-99% of the Romanian patients infected with hepatitis C virus (HCV). We present the genotyping tests recently performed on patients with HCV and advanced fibrosis eligible for the Direct-Acting Antiviral (DAA) therapy, as well as the prevalence of these cases across Romania. METHODS: The genotyping method was performed on 7,421 HCVpatients with advanced fibrosis. The detection method was automatic real time PCR platform M2000 (Abbott). Every subject was introduced into a database including age, sex, county and address. RESULTS: Genotype 1b was almost exclusively present: 7,392/7,421 (99.6%). Genotype 1b patients were 19.6% from Bucharest, 49% were males, with a median age of 60 years. Genotype non-1b was encountered in 29/7,421 subjects (0.4%), 62% were males, 69% from Bucharest and the median age was 52 years. Most of the subjects (75%) were in the 6th and 7th age decade. The prevalence of these cases varied significantly across Romanian counties: the highest was in Bucharest (61.3/105), Bihor (47/105), Iasi (46/105) and Constanta (43/105), and the lowest in Ilfov (2.8/105), Harghita (3.7/105), Covasna (5.4/105) and Maramures (8.8/105) (p<0.001). CONCLUSIONS: Genotype 1b is encountered in 99.6% of patients with chronic hepatitis C and advanced fibrosis from Romania. The presence of genotypes non-1b is more common in Bucharest, in males and at a younger age. There are significant differences regarding the distribution of these cases across Romania: the highest rates are in Bucharest, Bihor, Iasi and Constanta.
Authors: Daniela Manuc; Carmen Monica Preda; Irina Sandra; Cristian Baicus; Razvan Cerban; Ileana Constantinescu; Andrei Ovidiu Olteanu; Cosmin Alexandru Ciora; Teodora Manuc; Daniela Elena Chiriac; Andreea Elena Chifulescu; Mircea Diculescu; Cristian Tieranu; Lucian Negreanu; Gabriela Oprea-Calin; Mircea Manuc Journal: J Med Life Date: 2020 Jan-Mar